Case Report
Copyright ©The Author(s) 2018.
World J Clin Cases. Nov 6, 2018; 6(13): 707-715
Published online Nov 6, 2018. doi: 10.12998/wjcc.v6.i13.707
Table 1 Main laboratory work-up, imaging and histology studies from 2000 to 2018
TimeInvestigationsResults
February 10, 2000Physical examinationNon-specific, non-infective orbital inflammatory pseudotumor
July 9, 2003CTEnlargement of double lacrimal glands, parotid glands
Lacrimal glands biopsyLymphonid pseudotumor of double lacrimal glands
May 21, 2005CTEnlargement of parotid glands
B-ultrasonographyDiffused enlargement of parotid glands
November 2, 2005Blood routine examinationLYM%: 50.9% (20.0-50.0), LYM#: 2.11 × 10-9/L (1.10-3.20), EOS%: 13.6% (0.4-8.0), EOS#: 0.78 × 10-9/L (0.02-0.50), NEUT%: 68.0% (50.0-70.0), NEUT#: 6.62 × 10-9/L (2.00-7.00)
BiochemistryAST: 628.5 U/L (13.0-35.0), ALT: 648.4 U/L (7.0-40.0), ALP: 356 U/L (50-135), GGT: 422.9 U/L (7.0-45.0)
CTEnlargement of the head of pancreas
December 4, 2005ERCPImplantation of a biliary stent
March 6, 2006IGG, RFHigh levels of serum IgG, RF, Ig light chain KAP, Ig light chain LAM
March 31, 2006ERCPImplantation of two biliary stents
BiopsyExtensive lymphatic plasma cell infiltrated in focal lobular, salivary gland tissue was under the squamous mucosa
July 8, 2006IGG, RFLow levels of serum complement C3 and IgG and Ig light chain KAP, high level of Ig light chain LAM
November 4, 2006ComplementLow level of serum complement C3
ENA antibody, ANAHEp2-ANA: positive 1:100 (< 1;100), ENA-AbSSA: negative, ENA-AbSSB: negative
November 8, 2006ERCPRemove of the biliary stent
November 26, 2006CTNo enlargement of the head of pancreas
Physical examinationNormal eyeball, normal conjunctiva, eyelids without edema, normal light reaction
September 4, 2007Blood routine examinationNormal parameters
September 6, 2007Endocrine examinationsDetails seen in Table 2
October 10, 2007Renal function examinationNormal function
May 17, 2008MRIPituitary stalk thickening
October 7, 2009CTEnlargement of the head of pancreas
November 13, 2009Blood routine examinationLYM%: 46.0% (20.0-50.0), LYM#: 1.92 × 10-9/L (1.10-3.20), EOS%: 23.1% (0.4-8.0), EOS#: 0.89 × 10-9/L (0.02-0.50), NEUT%: 49.0% (50.0-70.0), NEUT#: 5.83 × 10-9/L (2.00-7.00)
December 14, 2009MRIEnlargement of the head of pancreas
September 20, 2011CTNormal volume of the head of pancreas
November 22, 2011Bone scanRib fracture
November 23, 2011Blood routine examinationLYM%: 22.6% (20.0-50.0), LYM#: 1.85 × 10-9/L (1.10-3.20), EOS%: 11.1.% (0.4-8.0), EOS#: 0.97 × 10-9/L (0.02-0.50), NEUT%: 59.0% (50.0-70.0), NEUT#: 4.83 × 10-9/L (2.00-7.00)
IGG, RFHigh levels of IgE, RF
November 24, 2011IGGIgG1: 7.670 g/L (4.900-11.400 ), IgG2: 3.540 g/L (1.500-6.400), IgG3: 0.103 g/L (0.200-1.100), IgG4: 8.650 g/L (0.020-2.000)
IGG, RFHigh levels of serum IgE and RF
July 5, 2012Blood routine examinationLYM%: 38.9% (20.0-50.0), LYM#: 3.99 × 10-9/L (1.10-3.20), EOS%: 1.6% (0.4-8.0), EOS#: 0.16 × 10-9/L (0.02-0.50), NEUT%: 51.8% (50.0-70.0), NEUT#: 5.32 × 10-9/L (2.00-7.00)
July 10, 2012MRINormal shapes of pituitary gland, lung and pancreas
April 3, 2018Blood routine examinationEOS%: 0.0% (0.4-8.0), EOS#: 0.00 × 10-9/L (0.02-0.50), LYM%: 15.0% (20.0-50.0), LYM#: 1.72 × 10-9/L (1.10-3.20), NEUT%: 82.6% (50.0-70.0), NEUT#: 9.44 × 10-9/L (2.00-7.00)
UrinalysisNormal, Only the WBC count 26.3/uL (0.0-23.0 )
BiochemistryUREA: 2.10 mmol/L (3.10-8.80), ALB: 36.10 g/L (40.00-55.00), AST: 43.6U/L (13.0-35.0), ALP: 43U/L (50-135), GGT: 5.1 U/L (7.0-45.0)
IGG, Complement, RFIgG: 25.10 g/L (7.00-16.00), IgA:1.51 g/L (0.70-4.00), IgM: 0.45 g/L (0.40-2.30g/l), C3: 0.56 g/L (0.90-1.80), C4: 0.088 g/L (0.100-0.400), RF: 356.00 IU/mL (0.00-19.00), IgG4: 23.300 g/L (0.020-2.000)
CTSevere interstitial lung lesions
Bladder biopsyChronic inflammation
May 7,2018IGGIgG4: 5.280 g/L (0.020-2.000)
CTNormal